Regular Physical Activity May Boost Mesothelioma Survival

Physical Activity Can Boost Mesothelioma Survival

There is new evidence that regular physical activity may help patients with mesothelioma live longer.  A Korean professor has just published the findings of his study on physical activity among lung cancer patients. The findings may be relevant for people with the lung-related cancer, pleural mesothelioma.   Dr. Junga Lee analyzed 11 studies. The studies included more than 6 million lung cancer patients and spanned a 19 year period.  Dr. Lee found that patients’ cardiorespiratory fitness, walking speed, and level of physical activity correlated with how long they lived. Even their leisure activities played a role.  Mesothelioma and Lung Cancer Pleural mesothelioma starts in the lining around the lungs. Because it does not arise from lung cancer cells, it is not … Continue reading Regular Physical Activity May Boost Mesothelioma Survival »

Pleural Effusion in Mesothelioma: Comparing Solutions

pleural effusion in mesothelioma

A new study says, when it comes to pleural effusion in mesothelioma, the two main solutions are pretty equal – with one exception.  Pleural effusion is a buildup of fluid in the space around the lungs. Over time, this fluid restricts the lungs and makes it hard to breathe. The problem is common in several types of cancer, including malignant mesothelioma.  In a new report, Taiwanese and Hong Kong researchers compared the two primary ways of dealing with pleural effusion in mesothelioma. They conclude that the two methods work equally well. But one of them usually means a longer hospital stay. Understanding Pleural Effusion in Mesothelioma The pleura are layers of thin membranes that surround the lungs. Pleural mesothelioma tumors … Continue reading Pleural Effusion in Mesothelioma: Comparing Solutions »

Epithelioid Mesothelioma and Lung Cancer: Biomarker Shows Which is Which

epthelioid mesothelioma and lung cancer

Researchers from Hiroshima University say they have found a nearly foolproof way to tell the difference between epithelioid mesothelioma and lung cancer.  This is critical because the prognosis can be very different between the two. They are also treated differently.  But epithelioid mesothelioma and lung cancer are similar in many ways. They cause many of the same symptoms. Even their cells look similar under the microscope. This can make it hard for doctors to deliver an accurate and timely diagnosis.  If the new findings are right, the biomarker identified by the Hiroshima researchers could be a diagnostic gamechanger.  Lung Adenocarcinoma or Pleural Mesothelioma? At first glance, epithelioid mesothelioma and lung cancer seem to be very different. Mesothelioma makes up about … Continue reading Epithelioid Mesothelioma and Lung Cancer: Biomarker Shows Which is Which »

Opdivo for Mesothelioma Recurrence is Safe and Effective, Study Finds

Opdivo for mesothelioma recurrence

A new Japanese study appears to show that Opdivo for mesothelioma recurrence after surgery is safe and effective.  Opdivo (nivolumab) is an immunotherapy drug similar to Keytruda (pembrolizumab). It blocks a protein called PD-L1. PD-L1 helps mesothelioma cells avoid detection by the immune system.  In the latest study, 35 patients received Opdivo for mesothelioma recurrence. More than three quarters of them experienced either stable or decreased disease. Understanding How Nivolumab Works Nivolumab is most often used to treat non-small cell lung cancer. It makes tumors more vulnerable to immune system attack. Pleural mesothelioma has many of the same characteristics as lung cancer. This is one reason researchers are hopeful about Opdivo for mesothelioma recurrence.  The primary treatment for mesothelioma is … Continue reading Opdivo for Mesothelioma Recurrence is Safe and Effective, Study Finds »

Herb-like Compound May Be Alternative Treatment for Mesothelioma

alternative treatment for mesothelioma

A man-made version of a traditional Chinese herb could be an alternative treatment for mesothelioma.  Turkish researchers have published a new study on a drug called halofuginone. The study shows the drug has significant anticancer effects on mesothelioma cells.  In an article in Cell Biology International, they explore how halofuginone affects mesothelioma and lung cancer cells.  Mesothelioma Patients Need Another Treatment Option Mesothelioma is an asbestos-linked cancer that is hard to treat. Pleural mesothelioma is the most common type. Pleural mesothelioma grows quickly. It usually causes few symptoms until it is very advanced.  Chemotherapy is the main treatment. When that stops working, many patients look for an alternative treatment for mesothelioma.  Scientists are studying immunotherapy, new kinds of radiotherapy, and … Continue reading Herb-like Compound May Be Alternative Treatment for Mesothelioma »

PD-L1 Expression and Mesothelioma Prognosis

PD-L1 expression and mesothelioma prognosis

The largest study yet on PD-L1 expression and mesothelioma prognosis shows that patients with more of this protein in their cells have poorer odds of survival. Programmed death ligand 1 (PD-L1) helps cancer cells evade immune system attack.  Other studies have suggested a link between PD-L1 expression and mesothelioma prognosis. But the new meta-analysis performed by two Chinese researchers appears to confirm it with an even bigger data set.  Understanding Mesothelioma Prognosis Malignant mesothelioma is an uncommon cancer that typically carries a poor prognosis. Many people diagnosed with mesothelioma lose their lives to the illness within a year.  But there are also many exceptions. Some mesothelioma survivors live for decades after a mesothelioma diagnosis. Australian Paul Kraus is an example. … Continue reading PD-L1 Expression and Mesothelioma Prognosis »

Photoimmunotherapy for Mesothelioma Reduces Tumor Volume in Mice

photoimmunotherapy for mesothelioma

Japanese researchers testing photoimmunotherapy for mesothelioma say they used the technology to successfully reduce the size of tumors in mice. Scientists at the National Cancer Institute in the US developed near-infrared photoimmunotherapy (NIR-PIT). It is a new type of cancer immunotherapy that uses a chemical to make some cells more sensitive to light. When light is directed at these cells, they die. In their new study of photoimmunotherapy for mesothelioma, the Japanese team targeted podoplanin. Podoplanin is a glycoprotein. Many mesothelioma tumors overexpress podoplanin.  Targeting Mesothelioma Tumors with Light Malignant mesothelioma is a fast-growing membrane cancer caused by asbestos exposure. Standard cancer therapies do not work well for mesothelioma. Cancer researchers around the world are looking for alternative treatments.  Immunotherapy … Continue reading Photoimmunotherapy for Mesothelioma Reduces Tumor Volume in Mice »

Predicting Kidney Damage from Chemotherapy for Mesothelioma

kidney damage from chemotherapy

It may be possible to predict which mesothelioma patients are at risk for kidney damage from chemotherapy and take steps to prevent it.  Japanese cancer researchers have linked a protein called megalin to cisplatin-related nephrotoxicity.  Cisplatin is one of the main drugs used to treat mesothelioma. The researchers say people with more megalin in their urine are more likely to have kidney damage from chemotherapy with cisplatin.  Kidney Damage is a Risk of Chemotherapy Malignant mesothelioma is a rare cancer with no cure. Although scientists are working on other options, chemotherapy is the main treatment for mesothelioma. Most patients have a combination of Alimta (pemetrexed) and the platinum-based drug cisplatin. One of the biggest risks with cisplatin is kidney damage … Continue reading Predicting Kidney Damage from Chemotherapy for Mesothelioma »

PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study

PD-L1 inhibitor nivolumab

A study of the PD-L1 inhibitor nivolumab showed “safety and efficacy” in mesothelioma patients who failed with other treatments.  Nivolumab is a type of immunotherapy marketed under the brand name Opdivo. It is similar to pembrolizumab (Keytruda) in that it blocks the tumor-promoting protein PD-L1. Nivolumab is most often used for patients with non-small cell lung cancer.  A multicenter phase II Japanese study found the PD-L1 inhibitor nivolumab helped a group of pleural mesothelioma patients live longer. Just as importantly, the side effects of the drug were “manageable”.  Human Trial of PD-L1 Inhibitor Nivolumab Chemotherapy with pemetrexed (Alimta) and cisplatin is the standard first-line treatment for pleural mesothelioma. But many patients either do not respond to chemotherapy or they stop … Continue reading PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study »

Immunotherapy Prompts “Remarkable Response” in Sarcomatoid Pleural Mesothelioma

sarcomatoid pleural mesothelioma

Japanese doctors are reporting a remarkable response from the immunotherapy drug nivolumab in a patient with sarcomatoid pleural mesothelioma.  Sarcomatoid pleural mesothelioma is a very rare form of a rare cancer. It accounts for about 10 percent of cases of malignant mesothelioma.  This subtype is typically less responsive to standard treatments than the more common epithelioid variety. But researches at Kyushu Hospital in Fukuoka, Japan say nivolumab turned things around for their patient when the case looked hopeless.  How is Sarcomatoid Pleural Mesothelioma DIfferent? Malignant mesothelioma is a cancer of the linings around organs. Pleural mesothelioma grows on the pleural membrane that surrounds the lungs.  There are three cell subtypes of mesothelioma. The three subtypes respond differently to mesothelioma treatments. … Continue reading Immunotherapy Prompts “Remarkable Response” in Sarcomatoid Pleural Mesothelioma »

Get your free copy of
“Surviving Mesothelioma” Today!